Heart Failure (HF): Scope of the Problem. Temporal Trends in Age-Adjusted Survival After HF Diagnosis. More malignant than most cancers
|
|
- Rosalyn Townsend
- 5 years ago
- Views:
Transcription
1 Evidence-Based Approaches to the Management of Heart Failure: Reducing Hospitalization and Improving Patient Outcomes Eldrin F. Lewis, MD, MPH Director of Cardiovascular Clerkship Brigham and Women s Hospital Harvard Medical School Boston, Massachusetts Patients in US (millions) Heart Failure (HF): Scope of the Problem US prevalence*: 5.8 million US annual incidence: 67, Annual mortality: 282, % depending on severity Cost: $39.2 billion 53% of cost due to hospitalization % HF increases with age 5 s 6 s 7 s >8 AHA Statistical Update. Circulation. 21;121:e46-e2. Croft JB et al. J Am Geriatr Soc. 1997;45: Rich M. J Am Geriatric Soc. 1997;45: Hospital discharges for heart failure by sex in United States: and Projected Temporal Trends in Age-Adjusted Survival After HF Diagnosis Go A S et al. Circulation. 213;127:e6-e245 Heidenreich P, et al. Circ Heart Fail 213. Men Women Levy D, et al. N Engl J Med. 22;347: More malignant than most cancers Projected Costs of Heart Failure Care Women Men 8% of costs related to hospitalization Heidenreich P, et al. Circ Heart Fail
2 Heart Failure Definition Heart Failure Symptoms Pathophysiology: The inability to provide adequate cardiac output to the body at rest or with exertion, or to do so only in the setting of elevated cardiac filling pressures. -E. Braunwald modified by B. Borlaug and M. Redfield Clinically: A clinical syndrome characterized by breathlessness, fatigue and edema caused by an abnormality of the heart Dyspnea Orthopnea Number of pillows Cough GI Effects Nausea, early satiety Fatigue Reduced perfusion to skeletal muscles Peripheral edema CNS effects Confusion, hallucinations Extremity effects Cool extremities Urinary effects Polyuria, nocturia Neurohormonal Activation in Heart Failure Treatment of Heart Failure Empiric and Evidence-Based Levels Plasma Plasma Renin Norepinephrine Activity (pg/ml) (ng/ml/h) Arginine Vasopressin (pg/ml) Atrial Natriuretic Peptide (pg/ml) Endothelin-1 (pg/ml) NL HF NL HF NL HF NL HF NL HF Adapted from Cohn JN. Cardiology. 1997;88(suppl 2):2 6 Pathophysiology Effect of ACE inhibition in patients with CHF Systemic vasoconstriction Renal sodium and water retention Myocardial injury Left ventricular systolic dysfunction Perceived reduction in circulating volume and pressure Mortality, % CONSENSUS* NYHA Class IV (n = 126) (n = 126) SOLVD Treatment NYHA Class II III (n = 1284) (n = 1285) Neurohormonal activation SNS RAAS ET, AVP etc Natriuretic peptides *Risk reduction 4% (P =.3). Months Risk reduction 16% (P =.36). Swedberg K et al for the CONSENSUS Trial Study Group. Circulation. 199;82: The SOLVD Investigators. N Engl J Med. 1991;325:
3 ACCF/AHA Guideline for the Management of Heart Failure ACE Inhibitors Generic Name Trade Name Initial Daily Dose Target Dose Mean Dose in Clinical Trials Captopril Capoten 6.25 mg tid 5 mg tid mg/day Vasotec 2.5 mg bid 1 mg bid 16.6 mg/day Fosinopril Monopril 5-1 mg qd 8 mg qd N/A Lisinopril Zestril, Prinivil mg qd 2 mg qd 4.5 mg/day, 33.2 mg/day* Quinapril Accupril 5 mg bid 8 mg qd N/A Ramipril Altace mg qd 1 mg qd N/A Trandolapril Mavik 1 mg qd 4 mg qd N/A *No mortality difference between high and low dose groups, but 12% lower risk of death or hospitalization in high dose group vs. low dose group. Losartan Heart Failure Survival Study: ELITE II Primary Endpoint All-Cause Mortality Probability of survival Captopril, (n=74), 25 events Losartan, (n=78), 28 events Losartan/captopril Hazard Ratio (95% CI): 1.13 (.95, 1.35) P= Days of follow-up Pitt et al Lancet. 2; 355: ARBs Class I: ARBs are recommended in patients with HFrEF with current or prior symptoms who are ACEI intolerant, unless contraindicated, to reduce morbidity and mortality Level of Evidence = A Class IIb: Addition of an ARB may be considered in persistently symptomatic patients with HFrEF who are already being treated with an ACEI and a β-blocker in whom an aldosterone antagonist is not indicated or tolerated Level of Evidence = A Routine combined use of an ACEI, ARB, and aldosterone receptor antagonist is potentially harmful for patients with HFrEF. Level of Evidence = C ARBs: Doses Generic Name Trade Name Initial Daily Dose Target Dose Mean Dose in Clinical Trials Candesartan Atacand 4 8 mg QD 32 mg QD 24 mg/day Losartan Cozaar mg QD NOT a class effect, target doses used in clinical trials. 5 mg QD 129 mg/day Valsartan Diovan 4 mg BID 16 mg BID 254 mg/day Circulation 213;128:e Beta-blockers are the most evidencebased therapy in heart failure MERIT-HF CIBIS-2 Have we pushed inhibiting the RAAS as far as we could go? COPERNICUS SENIORS 3
4 ACCF/AHA Guideline for the Management of Heart Failure Beta Blockers Generic Name Trade Name Initial Daily Dose Target Dose Mean Dose in Clinical Trials Bisoprolol Zebeta 1.25 mg qd 1 mg qd 8.6 mg/day Carvedilol Coreg mg bid 25 mg bid 37 mg/day Carvedilol Coreg CR 1 mg qd 8 mg qd Metoprolol succinate CR/XL Toprol XL mg qd 2 mg qd 9 mg/day The stunning success of ACE inhibitors and beta blockers in mild-moderate HF 1 year mortality (%) SOLVD-T CIBIS Clinical Tidbits: ACEI first, to low doses β-blocker at LOW dose; titrate to target or maximum tolerated dose Go back to titrate ACEI to target dose Diuretic/ digoxin Diuretic/ digoxin Diuretic/ digoxin Diuretic/ digoxin Beta-blocker Trials comparing an aldosterone/mr antagonist to placebo (added to an ACE inhibitor) in systolic HF Aldosterone Receptor Antagonists (ARAs or MRAs): ACCF/AHA Guidelines Probability of survival RALES 1663 NYHA class III/IV patients 95% ACE I/1% β blocker Spironolactone.5 RRR (95% CI) 3 (18 4)% P < Years from randomization Probability of survival EMPHASIS HF 2737 NYHA class II patients 93% ACE I or ARB/87% β blocker Eplerenone.5 RRR (95% CI) 22 (5 36)% P = Years from randomization Aldosterone receptor antagonists (or MRAs) are recommended in patients with NYHA class II IV and who have LVEF of 35% or less, unless contraindicated, to reduce morbidity and mortality. Strength of Evidence = A Aldosterone receptor antagonists are recommended to reduce morbidity and mortality after an acute MI in patients who have LVEF of 4% or less who develop symptoms of HF or who have a history of diabetes mellitus, unless contraindicated. Strength of Evidence = B Pitt B, et al. N Engl J Med. 1999;341: Zannad F, et al. N Engl J Med. 21;364: Circulation 213;128:e Aldosterone Antagonists: Doses MRAs: Contraindications Generic Name Trade Name Initial Daily Dose Target Dose Mean Dose in Clinical Trials Spironolactone Aldactone mg qd 25 mg qd 26 mg/day Eplerenone Inspra 25 mg qd 5 mg qd 42.6 mg/day Not recommended when: creatinine is > 2.5 mg/dl (or creatinine clearance is < 3 ml/minute) or serum potassium is > 5. mmol/l Level of Evidence = A Circulation 213;128:e
5 A-HeFT All-Cause Mortality (Hydralazine/isosorbide dinitrate) Hydralazine and Isosorbide Dinitrate Class I: The combination of hydralazine and isosorbide dinitrate is recommended to reduce morbidity and mortality for patients selfdescribed as African Americans with NYHA class III IV HFrEF receiving optimal therapy with ACEIs and β-blockers, unless contraindicated Level of Evidence = A Class IIa: A combination of hydralazine and isosorbide dinitrate can be useful to reduce morbidity or mortality in patients with current or prior symptomatic HFrEF who cannot be given an ACEI or ARB because of drug intolerance, hypotension, or renal insufficiency, unless contraindicated Level of Evidence = B Taylor AL. N Engl J Med 24;351: Reprinted with permission from Massachusetts Medical Society. Circulation 213;128:e ICD Therapy in HF: MADIT-II and SCD-HeFT Cumulative benefit of poly-pharmacy (and CRT) in severe HF 35 RALES year mortality (%) COPERNICUS CARE-HF Moss et al, New Engl J Med 22 Bardy et al, New Engl J Med 25 Aldo. antag. Aldo. antag. Aldo. antag Beta-blocker Aldo. antag Beta-blocker Aldo. antag Beta-blocker CRT Evidence-Based Approaches to the Management of Heart Failure: Reducing Hospitalization and Improving Patient Outcomes Gregg C. Fonarow, MD, FAHA, FACC, FHFSA Eliot Corday Professor of Cardiovascular Medicine and Science Director, Ahmanson-UCLA Cardiomyopathy Center Co-Chief, UCLA Division of Cardiology Co-Director, UCLA Preventative Cardiology Program David Geffen School of Medicine at UCLA Los Angeles, California Sinus node inhibition with Ivabradine MOA: Blocks the hyperpolarization-activated cyclic nucleotidegated (HCN) channel in the sinoatrial node, responsible for the I f current Delays diastolic depolarization Does not affect other ion channels Does not alter myocardial contractility and intra-cardiac conduction 5
6 SHIFT Study Design Patients > 18 years old NSR & HR 7 bpm NYHA FC II-IV and stable on meds for 4 wks LVEF 35% On target or maximally tolerated doses of BB Hospitalization for worsening HF in 12 mo 14 day run-in (N=6558) Ivabradine 5mg BID x 2 weeks, then 7.5mg BID N=3268 BID N=329 Median f/u duration 22.9 months SHIFT Study Results Number of Events Outcome Ivabradine HR (95% CI) ARR CV Death or HF Hospitalization (.75,.9) 4.2% CV Death (.8, 1.3) 1.1% HF Hospitalization (.66,.83) 4.7% The treatment effect reflected only a reduction in the risk of hospitalization for worsening HF; there was no benefit observed for the mortality component of the primary endpoint Adverse Drug Reactions with Rates 1% on Ivabradine versus Adverse Reaction Ivabradine N=326 N=3278 Bradycardia 1% 2.2% Hypertension 8.9% 7.8% Atrial Fibrillation 8.3% 6.6% Phosphenes (visual brightness)* 2.8%.5% *inhibition of the retinal current I h, responsible for curtailing retinal responses to bright light stimuli. Most pronounced under triggering circumstances (rapid changes in brightness) Ivabradine Considerations Indication: To reduce the risk of hospitalization for worsening HF in patients with stable, symptomatic chronic HF LVEF 35% In sinus rhythm with resting heart rate 7 beats/minute Either on maximally tolerated doses of β-blockers or have a contraindication to β-blocker use Doses: Starting dose 5 mg twice daily, up to 7.5mg twice daily 216 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 213 ACCF/AHA Guideline for the Management of Heart Failure Ivabradine can be beneficial to reduce HF hospitalization for patients with symptomatic (NYHA class II-III) stable chronic HFrEF (LVEF 35%) who are receiving GDEM, including a beta blocker at maximum tolerated dose, and who are in sinus rhythm with a heart rate of 7 bpm or greater at rest (IIa, B-R) Only 25% of patients studied in SHIFT were on optimal doses of beta-blocker therapy. It is important to initiate and up titrate these agents to target doses, as tolerated, before assessing the resting heart rate for consideration of ivabradine initiation Would Dual Blockade of the RAS with Evidenced- Based Background Therapy be Superior to Singleagent RAS Inhibition? Primary outcome: CV death or heart failure hospitalization + 5-1mg bid Aliskirenmg qd Open-label run-in 4-12 weeks Prior ACEi use discontinued Randomization 5-1mg bid (n=2336) Aliskiren 3mg qd (n=234) 5-1mg bid + Aliskiren3mg qd (n=234) Double-blind Median follow-up = 36.6 months McMurray et al. NEJM 216 6
7 Direct Renin Inhibition and ACE Inhibition Similar DUAL Inhibition NO BETTER and Produced More Side Effects PARADIGM-HF: Study Design Combo Ali Ena Hypotension 13.8% 1.6% 11.% Renal 4.1% 2.7% 2.7% Impairment Hyperkalemia 17.1% 1.9% 12.5% Randomization (N = 8442 patients) 1 mg bid Single-blind run-in period 1 mg bid 2 mg bid 2 mg bid Primary outcome: CV death or heart failure hospitalization Testing tolerability to target doses of enalapril and 1 mg bid On top of standard heart failure therapy (excluding ACEIs and ARBs) 2 weeks 1-2 weeks 2-4 weeks ~ 21 to 43 months (event-driven) McMurray et al. NEJM 216 McMurray et al. NEJM 214 PARADIGM-HF: Cardiovascular Death or Heart Failure Hospitalization (Primary Endpoint) Kaplan-Meier Estimate of Cumulative Rates (%) Patients at Risk (n=4212) (n=4187) HR =.8 ( ) P =.4 Number needed to treat = Days After Randomization PARADIGM-HF: Cardiovascular Death Kaplan-Meier Estimate of Cumulative Rates (%) HR =.8 ( ) P =.8 Number need to treat = 32 (n=4212) (n=4187) Days After Randomization Patients at Risk PARADIGM-HF: All-Cause Mortality PARADIGM-HF: Adverse Events Kaplan-Meier Estimate of Cumulative Rates (%) HR =.84 ( ) P<.1 (n=4212) (n=4187) Days After Randomization Patients at Risk (n=4187) Prospectively identified adverse events (n=4212) P Value Symptomatic hypotension <.1 Serum potassium > 6. mmol/l Serum creatinine > 2.5 mg/dl Cough <.1 Discontinuation for adverse event Discontinuation for hypotension NS Discontinuation for hyperkalemia 11 NS Discontinuation for renal impairment Angioedema (adjudicated) Medications, no hospitalization 16 9 NS Hospitalized; no airway compromise 3 1 NS Airway compromise
8 Early Benefit of PARADIGM-HF: Mode of Death All causes CV causes Sudden Worsening HF Months after Randomization Packer et al. Circulation 214 Number HR p= < Desai et al. Eur Heart J. 2 PARADIGM-HF: Hospitalization for HF (%) Proportion of patients HR.79 (.71,.89) p <.1 Patients hospitalized Number of admissions RR.77 (.67,.89) p =.4 Hospitalizations Packer et al. Circulation 214 Sacubitril/Valsartan was Effective Across a Spectrum of Risk: The MAGGIC Risk Score RATE PER1 PATIENT YEARS CV death or HF hospitalisation QUINTILE OF RISK SCORE Simpson et al. JACC 2 LCZ was effective across the spectrum of Ejection Fraction PARADIGM Enrolled > 2 patients with EF between 35-4%! PARADIGM-HF: Baseline mineralocorticoid receptor antagonist use Cardiovascular death HR.8 (.71,.89); p <.1 HR.75 (.63,.89)* HR.84 (.73,.98)* (%) Patients on an MRA and were ~4% more likely to develop SEVERE hyperkalemia than those on MRA and sacubitril/valsartan Solomon et al. Circulation HF 216 MRA - No MRA - Yes *Interaction p =.32 NEJM 214, ACC 216, AHA 216 8
9 Effect of Sacubitril/Valsartan in the Most Stable Patients Influence of Sacubitril/Valsartan on 3- Day Readmission 2% of the most stable patients had a primary event and 17% died In the most stable patients with a primary event, death occurred prior to a heart failure hospitalization in 51%, and 6% of these deaths were sudden Solomon et al. JACC-HF 216 Desai et al. JACC 216 Estimated Long-Term Benefit of HF Free Survival with Sacubitril/Valsartan Potential Mortality Reduction with Optimal Implementation of ARNI Claggett et al. NEJM 2 Fonarow et al. JAMA Cardiol 216 Natriuretic Peptides: NT-proBNP and BNP Mechanism: NT-proBNP and BNP Cardiomyocyte Blood Mair et al. Clin Chem Lab Med 21 NT-proBNP NT-proBNP remains an accurate measure of 1 severity of HF in the setting of treatment with but BNP 2 will not 4be reliable! 6 8 Pre Run-in Baseline NT-proBNP BNP Months BNP McMurray et al. NEJM 214 9
10 216 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for HF 216 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for HF The clinical strategy of inhibition of the renin-angiotensin system with ACE inhibitors (Level of Evidence: A), OR ARBs (Level of Evidence: A), OR ARNI (Level of Evidence: B-R) in conjunction with evidence-based beta blockers, and aldosterone antagonists in selected patients, is recommended for patients with chronic HFrEF to reduce morbidity and mortality The use of ACE inhibitors is beneficial for patients with prior or current symptoms of chronic HFrEF to reduce morbidity and mortality (IA) The use of ARBs to reduce morbidity and mortality is recommended in patients with prior or current symptoms of chronic HFrEF who are intolerant to ACE inhibitors (IA) In patients with chronic symptomatic HFrEF NYHA class II or III who tolerate an ACE inhibitor or ARB, replacement by an ARNI is recommended to further reduce morbidity and mortality (IB-R) Yancy et al. JACC 216 Yancy et al. JACC 216 Sacubitril/Valsartan Dosing HFpEF accounts for up to Half of HF Doses: 24/26 mg, 49/51 mg, 97/13 mg Starting doses: 49/51 mg twice daily for patients previously on ACEI or ARB 24/26 mg for low dose ACEI/ARB ( 1mg enalapril daily) or ACEI/ARB naive MUST have 36 hours washout between ACEI dose and sacubitril/valsartan initiation OPTIMIZE-HF Registry, N=41,267 HFrEF HFpEF Fonarow et al. JACC 27 Similar Signs and Symptoms in Patients with HFpEF and HFrEF % HFrEF HFpEF Outcomes Trials in HFpEF CHARM-Preserved I-PRESERVE PEP-CHF TOPCAT Edema PND Rest dyspnea S 3 Crackles JVP >6 cm Orthopnea Cardiomegaly CHARM Investigators 1
11 TOPCAT: 1 Outcome (CV Death, HF Hosp, or Resuscitated Cardiac Arrest) TOPCAT: Heart Failure Hospitalizations 351/1723 (2.4%) Total HF Hosp: Spiro 394, 475; P<.1 Spironolactone HR =.89 ( ) p= /1722 (18.6%) 245/1723 (14.2%) 26/1722 (12.%) Spironolactone HR =.83 (.69.99) p=.42 Pitt et al. NEJM 214 Exploratory: vs. Spiro by Region 216 ESC Guideline Update US, Canada, Argentina, Brazil HR=.82 ( ) Interaction p=.122 Russia, Rep Georgia HR=1.1 ( ) : 28/881 (31.8%) : 71/842 (8.4%) No treatment has yet been shown to reduce morbidity and mortality in patients with HFpEF Diuretics are used to control sodium and water retention and relieve breathlessness and edema as in HFrEF Adequate treatment of hypertension and ischemia is also considered to be important Ponikowski et al. Eur Heart J 216 PARAMOUNT: Significant Reduction in NTproBNP with at 12 Weeks (733,112) 835 (71, 981) NT-proBNP (pg/ml) p = (67,914) 5 1 Weeks Post Randomization 12 Valsartan /Valsartan:.77 (.64,.92) P =.5 65 (512, 714) Solomon et al. Lancet 212 PARAGON-HF: Prospective comparison of ARNI with ARB Global Outcomes in heart failure with preserved ejection fraction A randomized, double blind, trial to evaluate the long-term efficacy and safety profile of the angiotensin receptor neprilysin inhibitor (ARNI),, compared with valsartan, in patients with heart failure with preserved ejection fraction (HFpEF) NCT
12 Summary Heart failure remains extremely morbid and deadly Current treatment of HFrEF is both empiric (diuretics, lifestyle) and evidenced-based (ACEIs, ARBs, Beta- Blockers, MRAs) Devices used for specific subsets (ICD for reduced EF, CRT for reduced EF and wide QRS/LBBB, LVAD for end-stage or bridge to transplant) In HFpEF, current treatment remains empiric, with some evidence that RAAS blockade can be useful in some patients Clinical trials in HFpEF are ongoing with novel agents 12
Heart Failure (HF): Scope of the Problem. Temporal Trends in Age-Adjusted Survival After HF Diagnosis. More malignant than most cancers
Patients in US (millions) Heart Failure (HF): Scope of the Problem 1 4 2 3.5 4. 1. 1991 21 237 US prevalence*: 5. million US annual incidence: 7, Annual mortality: 22,754 5-1% depending on severity Cost:
More informationHeart Failure (HF): Scope of the Problem. Temporal Trends in Age-Adjusted Survival After HF Diagnosis. More malignant than cancer
Patients in US (millions) Heart Failure (HF): Scope of the Problem 1 8 6 4 2 3.5 4.8 1. 1991 21 237 US prevalence*: 5.8 million US annual incidence: 67, Annual mortality: 282,754 5-1% depending on severity
More informationLearning Objectives. Heart Failure (HF): Scope of the Problem. Temporal Trends in Age-Adjusted Survival After HF Diagnosis
7:5 :5 am Update in Heart Failure SPEAKER Orly Vardeny, PharmD, MS Presenter Disclosure Information The following relationships exist related to this presentation: Orly Vardeny, PharmD, MS: Advisory Board
More informationDisclosures. Overview. Goal statement. Advances in Chronic Heart Failure Management 5/22/17
Disclosures Advances in Chronic Heart Failure Management I have nothing to disclose Van N Selby, MD UCSF Advanced Heart Failure Program May 22, 2017 Goal statement To review recently-approved therapies
More information1/4/18. Heart Failure Guideline Review and Update. Disclosure. Pharmacist Objectives. Pharmacy Technician Objectives. What is Heart Failure?
Disclosure Heart Failure Guideline Review and Update I have had no financial relationship over the past 12 months with any commercial sponsor with a vested interest in this presentation. Natalie Beiter,
More informationDisclosures. Advances in Chronic Heart Failure Management 6/12/2017. Van N Selby, MD UCSF Advanced Heart Failure Program June 19, 2017
Advances in Chronic Heart Failure Management Van N Selby, MD UCSF Advanced Heart Failure Program June 19, 2017 I have nothing to disclose Disclosures 1 Goal statement To review recently-approved therapies
More informationOutline. Classification by LVEF Conventional Therapy New Therapies. Ivabradine Sacubitril/valsartan
New Pharmacological Therapies for Heart Failure Mark Drazner, MD, MSc Clinical Chief of Cardiology Medical Director, CHF/VAD/Transplant James M. Wooten Chair in Cardiology UT Southwestern Medical Center
More informationDrugs acting on the reninangiotensin-aldosterone
Drugs acting on the reninangiotensin-aldosterone system John McMurray Eugene Braunwald Scholar in Cardiovascular Diseases, Brigham and Women s Hospital, Boston & Visiting Professor, Harvard Medical School
More informationBeyond ACE-inhibitors for Heart Failure. Jacob Townsend, MD NCVH Birmingham 2015
Beyond ACE-inhibitors for Heart Failure Jacob Townsend, MD NCVH Birmingham 2015 % Decrease in Mortality Current Therapy HFrEF 0% Angiotensin receptor blocker ACE inhibitor Beta blocker Mineralocorticoid
More informationChecklist for Treating Heart Failure. Alan M. Kaneshige MD, FACC, FASE Oklahoma Heart Institute
Checklist for Treating Heart Failure Alan M. Kaneshige MD, FACC, FASE Oklahoma Heart Institute Novartis Disclosure Heart Failure (HF) a complex clinical syndrome that arises secondary to abnormalities
More informationTreating HF Patients with ARNI s Why, When and How?
Treating HF Patients with ARNI s Why, When and How? 19 th Annual San Diego Heart Failure Symposium for Primary Care Physicians January 11-12, 2019 La Jolla, CA Barry Greenberg M.D. Distinguished Professor
More informationHEART FAILURE: PHARMACOTHERAPY UPDATE
HEART FAILURE: PHARMACOTHERAPY UPDATE 3 HEART FAILURE REVIEW 1 5.1 million x1.25 = 6.375 million 40 years old = MICHAEL F. AKERS, PHARM.D. CLINICAL PHARMACIST CENTRACARE HEALTH, ST. CLOUD HOSPITAL HF Diagnosis
More information2017 Summer MAOFP Update
2017 Summer MAOFP Update. Cardiology Update 2017 Landmark Trials Change Practice Guidelines David J. Strobl, DO, FNLA Heart Failure: Epidemiology More than 4 million patients affected 400,000 new cases
More informationSatish K Surabhi, MD.FACC,FSCAI,RPVI Medical Director, Cardiac Cath Labs AnMed Health Heart & Vascular Care
Satish K Surabhi, MD.FACC,FSCAI,RPVI Medical Director, Cardiac Cath Labs AnMed Health Heart & Vascular Care None Fig. 1. Progression of Heart Failure.With each hospitalization for acute heart failure,
More informationContemporary Management of Heart Failure. Keerthy K Narisetty, MD Comprehensive Heart Failure Management Program BHHI Primary Care Symposium
Contemporary Management of Heart Failure Keerthy K Narisetty, MD Comprehensive Heart Failure Management Program BHHI Primary Care Symposium Disclosures I have no relevant relationships with commercial
More informationUnderstanding and Development of New Therapies for Heart Failure - Lessons from Recent Clinical Trials -
Understanding and Development of New Therapies for Heart Failure - Lessons from Recent Clinical Trials - Clinical trials Evidence-based medicine, clinical practice Impact upon Understanding pathophysiology
More informationFrom PARADIGM-HF to Clinical Practice. Waleed AlHabeeb, MD, MHA Associate Professor of Medicine President of the Saudi Heart Failure Group
From PARADIGM-HF to Clinical Practice Waleed AlHabeeb, MD, MHA Associate Professor of Medicine President of the Saudi Heart Failure Group PARADIGM-HF: Inclusion Criteria Chronic HF NYHA FC II IV with LVEF
More informationCongestive Heart Failure 2015
Definition Congestive Heart Failure 215 JP Mehegan/ Mercy Cardiology n Cardiac failure; Congestive heart failure; Chronic heart failure (synonyms) n When the heart is unable to pump sufficiently and at
More informationNew Paradigms in Rx of Symptomati Heart Failure:Role of Ivabradine & Angiotensin Neprilysin Inhibition
New Paradigms in Rx of Symptomati Heart Failure:Role of Ivabradine & Angiotensin Neprilysin Inhibition Prakash Deedwania, MD, FACC, FACP, FCCP, FAHA Professor of Medicine, UCSF School of Medicine, Director,
More informationHeart Failure Pearls in the Ambulatory Care Setting: A Scenario Based Approach
Heart Failure Pearls in the Ambulatory Care Setting: A Scenario Based Approach Presented by the ACCP Ambulatory Care PRN and Cardiology PRN Erika Hellenbart, PharmD, BCPS Zachary Klick, PharmD, BCPS Orly
More informationUpdates in Heart Failure (HF) 2016: ACC / AHA and ESC
Updates in Heart Failure (HF) 2016: ACC / AHA and ESC Patrick McBride, MD, MPH Professor of Medicine & Family Medicine, UW School of Medicine and Public Health Special thanks to: Clyde W. Yancy, MD, MSc
More informationESC Guidelines for the Diagnosis and Treatment of Chronic Heart Failure
ESC Guidelines for the Diagnosis and Treatment of Chronic Heart Failure - 2005 Karl Swedberg Professor of Medicine Department of Medicine Sahlgrenska University Hospital/Östra Göteborg University Göteborg
More informationDisclosures for Presenter
A Comparison of Angiotensin Receptor- Neprilysin Inhibition (ARNI) With ACE Inhibition in the Long-Term Treatment of Chronic Heart Failure With a Reduced Ejection Fraction Milton Packer, John J.V. McMurray,
More informationCombination of renin-angiotensinaldosterone. how to choose?
Combination of renin-angiotensinaldosterone system inhibitors how to choose? Karl Swedberg Professor of Medicine Sahlgrenska Academy University of Gothenburg karl.swedberg@gu.se Disclosures Research grants
More informationSacubitril/Valsartan in HFrEF for All Protagonist View George Honos MD FRCPC FCCS FACC
Sacubitril/Valsartan in HFrEF for All Protagonist View George Honos MD FRCPC FCCS FACC Head of Cardiology Medical Manager / CV Program CHUM Disclosure Statement Within the past two years: I have had an
More informationLITERATURE REVIEW: HEART FAILURE. Chief Residents
LITERATURE REVIEW: HEART FAILURE Chief Residents Heart Failure EF 40% HFrEF Problem with contractility EF 40-50% HFmrEF EF > 50% HFpEF Problem with filling/relaxation RISK FACTORS Post MI HTN DM Obesity
More informationI know the trials in heart failure but how do I manage my patient? Dosing of neurohormones antagonists
I know the trials in heart failure but how do I manage my patient? Dosing of neurohormones antagonists Alessandro Fucili (Ferrara, IT) Massimo F Piepoli (Piacenza, IT) Clinical Case: 82 year old woman
More informationThe ACC Heart Failure Guidelines
The ACC Heart Failure Guidelines Fakhr Alayoubi, Msc,R Ph President of SCCP Cardiology Clinical Pharmacist Assistant Professor At King Saud University King Khalid University Hospital Riyadh-KSA 2017 ACC/AHA/HFSA
More informationWhat s New in Heart Failure? Marie-France Gauthier, BSc, PharmD, ACPR Clinical Pharmacist at Montfort Hospital
What s New in Heart Failure? Marie-France Gauthier, BSc, PharmD, ACPR Clinical Pharmacist at Montfort Hospital Disclosures I have no current or past relationships with commercial entities Learning objectives
More informationA patient with decompensated HF
A patient with decompensated HF Professor Michel KOMAJDA University Pierre & Marie Curie Pitie Salpetriere Hospital Department of Cardiology Paris (France) Declaration Of Interest 2010 Speaker : Servier,
More informationCT Academy of Family Physicians Scientific Symposium October 2012 Amit Pursnani, MD
CT Academy of Family Physicians Scientific Symposium October 2012 Amit Pursnani, MD Clinical syndrome resulting from a structural or functional cardiac disorder that impairs the ability of the heart to
More informationHFpEF, Mito or Realidad?
HFpEF, Mito or Realidad? Ileana L. Piña, MD, MPH Professor of Medicine and Epidemiology/Population Health Associate Chief for Academic Affairs -- Cardiology Montefiore-Einstein Medical Center Bronx, NY
More informationOptimal blockade of the Renin- Angiotensin-Aldosterone. in chronic heart failure
Optimal blockade of the Renin- Angiotensin-Aldosterone Aldosterone- (RAA)-System in chronic heart failure Jan Östergren Department of Medicine Karolinska University Hospital Stockholm, Sweden Key Issues
More informationGuideline-Directed Medical Therapy
Guideline-Directed Medical Therapy Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation OPTIMAL THERAPY (As defined in
More informationUpdate on pharmacological treatment of heart failure. Aldo Pietro Maggioni, MD, FESC ANMCO Research Center Firenze, Italy
Update on pharmacological treatment of heart failure Aldo Pietro Maggioni, MD, FESC ANMCO Research Center Firenze, Italy Presenter Disclosures Dr. Maggioni : Serving in Committees of studies sponsored
More informationHeart Failure Medical and Surgical Treatment
Heart Failure Medical and Surgical Treatment Daniel S. Yip, M.D. Medical Director, Heart Failure and Transplantation Mayo Clinic Second Annual Lakeland Regional Health Cardiovascular Symposium February
More informationHeart Failure: Current Management Strategies
Heart Failure: Current Management Strategies CSHP Fall Education Session- September 30th, 2017 Carolyn MacKinnon & Tamara Matchett BscPharm, ACPR Candidates Objectives 1. Describe the pathophysiology &
More informationDISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.
DISCLAIMER: Video will be taken at this clinic and potentially used in Project ECHO promotional materials. By attending this clinic, you consent to have your photo taken and allow Project ECHO to use this
More informationHeart Failure Management. Waleed AlHabeeb, MD, MHA Assistant Professor of Medicine Consultant Heart Failure Cardiologist
Heart Failure Management Waleed AlHabeeb, MD, MHA Assistant Professor of Medicine Consultant Heart Failure Cardiologist Heart failure prevalence is expected to continue to increase¹ 21 MILLION ADULTS WORLDWIDE
More informationContemporary Advanced Heart Failure Therapy
Contemporary Advanced Heart Failure Therapy Andrew Boyle, MD Professor of Medicine Medical Director of Advanced Heart Failure Thomas Jefferson University Philadelphia, PA Audience Response Question 40
More informationSummary/Key Points Introduction
Summary/Key Points Introduction Scope of Heart Failure (HF) o 6.5 million Americans 20 years of age have HF o 960,000 new cases of HF diagnosed annually o 5-year survival rate for HF is ~50% Classification
More informationESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure
Patients t with acute heart failure frequently develop chronic heart failure Patients with chronic heart failure frequently decompensate acutely ESC Guidelines for the Diagnosis and A clinical response
More informationESC Guidelines for diagnosis and management of HF 2012: What s new? John Parissis, MD Athens, GR
ESC Guidelines for diagnosis and management of HF 2012: What s new? John Parissis, MD Athens, GR Disclosures ALARM INVESTIGATOR RESEARCH GRANTS BY ABBOTT USA AND ORION PHARMA The principal changes from
More informationTERAPIA DELLO SCOMPENSO DAI BETA- BLOCCANTI AGLI ARNI (ARNI SI ARNI NO) Iseo 10 Novembre 2018
TERAPIA DELLO SCOMPENSO DAI BETA- BLOCCANTI AGLI ARNI (ARNI SI ARNI NO) Iseo 10 Novembre 2018 Carlo Lombardi Cattedra di Cardiologia Università e Spedali Civili di Brescia All-cause mortality in the European
More informationSystolic Dysfunction Clinical /Hemodynamic Guide for Management From Neprilysin Inhibitors to Ivabradine
Systolic Dysfunction Clinical /Hemodynamic Guide for Management From Neprilysin Inhibitors to Ivabradine Donna Mancini MD Choudhrie Professor of Cardiology Columbia University Speaker Disclosure Amgen
More informationManagement of Heart Failure in Older Adults
Management of Heart Failure in Older Adults New Data, New Guidelines, New Challenges JOSE NATIVI, MD, MSCI Assistant Professor of Medicine Cardiovascular Director Amyloidosis Program DISCLOSURES - Advisory
More informationHFpEF 2016 : Comorbidities and Outcomes
HFpEF 2016 : Comorbidities and Outcomes Christopher M. O Connor, MD, FACC CEO and Executive Director, Inova Heart and Vascular Institute Professor of Medicine, Duke University Editor in Chief, JACC: Heart
More informationUpdate in Congestive Hear Failure DRAGOS VESBIANU MD
Update in Congestive Hear Failure DRAGOS VESBIANU MD Case 58 yo AAM c/o shortness of breath for 3 weeks. Used to walk one mile per day and now he has noticed that he gets short of breath after 2 blocks.
More information9/10/ , American Heart Association 2
Clyde W. Yancy, MD, MSc, MACC, FAHA, MACP Vice Dean, Diversity & Inclusion Magerstadt Professor of Medicine Professor of Medical Social Sciences Chief, Division of Cardiology Northwestern University, Feinberg
More informationBalanced information for better care. Heart failure: Managing risk and improving patient outcomes
Balanced information for better care Heart failure: Managing risk and improving patient outcomes Heart failure increases hospitalization Heart failure is the most common medical reason for hospitalization
More informationBehandlungsalgorithmus bei Herzinsuffizienz mit reduzierter Auswurffraktion
Behandlungsalgorithmus bei Herzinsuffizienz mit reduzierter Auswurffraktion Professor Dr. med. Roger Hullin Leiter Programm für Schwere Herzinsuffizienz, VAD & Herztransplantation Suisse Romande Klinik
More informationACE inhibitors: still the gold standard?
ACE inhibitors: still the gold standard? Session: Twenty-five years after CONSENSUS What have we learnt about the RAAS in heart failure? Lars Køber, MD, D.Sci Department of Cardiology Rigshospitalet University
More informationHeart Failure Clinician Guide JANUARY 2018
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Heart Failure Clinician Guide JANUARY 2018 Introduction This evidence-based guideline summary is based on the 2018 National Heart Failure Guideline.
More informationBeta-blockers in heart failure: evidence put into practice
Beta-blockers in heart failure: evidence put into practice John McMurray Professor of Medical Cardiology, University of Glasgow & Consultant Cardiologist,Western Infirmary, Glasgow, UK Eugene Braunwald
More informationHeart Failure Clinician Guide JANUARY 2016
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Heart Failure Clinician Guide JANUARY 2016 Introduction This evidence-based guideline summary is based on the 2016 National Heart Failure Guideline.
More informationNeprilysin Inhibitor (Entresto ) Prior Authorization and Quantity Limit Program Summary
Neprilysin Inhibitor (Entresto ) Prior Authorization and Quantity Limit Program Summary FDA APPROVED INDICATIONS DOSAGE 1 Indication Entresto Reduce the risk of cardiovascular (sacubitril/valsartan) death
More informationHow Do You Mend a Broken Heart: The New Agents to Treat HF Paradigm Shift or Just the Same Old Drugs?
How Do You Mend a Broken Heart: The New Agents to Treat HF Paradigm Shift or Just the Same Old Drugs? Gregg C. Fonarow, MD FACC, FAHA, FHFSA Co-Chief UCLA Division of Cardiology Director, Ahmanson-UCLA
More informationDisclosures. This speaker has indicated there are no relevant financial relationships to be disclosed.
Disclosures This speaker has indicated there are no relevant financial relationships to be disclosed. And the Beat Goes On: New Medications for Heart Failure Alison M. Walton, PharmD, BCPS The Case of
More informationHighlight Session Heart failure and cardiomyopathies Michel KOMAJDA Paris France
Highlight Session 2014 Heart failure and cardiomyopathies Michel KOMAJDA Paris France # esccongress www.escardio.org/esc2014 HEART FAILURE AND CARDIOMYOPATHIES TOPIC 1 Drug Therapy TOPIC 2 Device Therapy
More information2/15/2017. Disclosures. Heart Failure = Big Problem. Heart Failure Update Reducing Hospitalizations and Improving Patient Outcomes 02/18/2017
Heart Failure Update Reducing Hospitalizations and Improving Patient Outcomes 02/18/2017 Julio A. Barcena, M.D. South Miami Heart Specialists Disclosures I have no relevant commercial relationships to
More informationAldosterone Antagonism in Heart Failure: Now for all Patients?
Aldosterone Antagonism in Heart Failure: Now for all Patients? Inder Anand, MD, FRCP, D Phil (Oxon.) Professor of Medicine, University of Minnesota, Director Heart Failure Program, VA Medical Center 111C
More informationUPDATES IN MANAGEMENT OF HF
UPDATES IN MANAGEMENT OF HF Jennifer R Brown MD, MS Heart Failure Specialist Medstar Cardiology Associates DC ACP Meeting Fall 2017 Disclosures: speaker bureau for novartis speaker bureau for actelion
More informationHeart Failure Guidelines For your Daily Practice
Heart Failure Guidelines For your Daily Practice Juan M. Aranda, Jr., MD, FACC, FHFSA Professor of Medicine Director of Heart Failure and Cardiac Transplantation University of Florida College of Medicine
More information2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure
2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure Developed in Collaboration With the American Academy of Family Physicians, American College of Chest
More informationDISCLOSURES ACHIEVING SUCCESS THROUGH FAILURE: UPDATE ON HEART FAILURE WITH PRESERVED EJECTION FRACTION NONE
ACHIEVING SUCCESS THROUGH FAILURE: UPDATE ON HEART FAILURE WITH PRESERVED EJECTION FRACTION Lori M. Tam, MD Providence Heart Institute DISCLOSURES NONE 1 OUTLINE Systolic vs. Diastolic Heart Failure New
More informationDECLARATION OF CONFLICT OF INTEREST
DECLARATION OF CONFLICT OF INTEREST TAKE HOME MESSAGES FROM RECENT HEART FAILURE CLINICAL TRIALS How to use aldosterone blockers? Faiez Zannad INSERM, U961 and Clinical Investigation Center CHU, Heart
More informationHeart Failure Background, recognition, diagnosis and management
Heart Failure Background, recognition, diagnosis and management Speaker bureau: Novartis At the conclusion of this activity, participants will be able to: Recognize signs and symptoms of heart failure
More informationHeart Failure A Team Approach Background, recognition, diagnosis and management
Heart Failure A Team Approach Background, recognition, diagnosis and management Speaker bureau: Novartis At the conclusion of this activity, participants will be able to: Recognize signs and symptoms of
More informationHeart Failure New Drugs- Updated Guidelines
Heart Failure New Drugs- Updated Guidelines Eileen Handberg, PhD, ANP-BC, FAHA, FACC Professor of Medicine Division of Cardiovascular Medicine University of Florida Disclosures 1. 3 2. 6 3. 8 4. 11 Dunlay
More information2017 CCS HF Guidelines Medical Therapy for HFrEF When What Order and How Much?
2017 CCS HF Guidelines Medical Therapy for HFrEF When What Order and How Much? Dr. Shelley Zieroth University of Manitoba @ShelleyZieroth @CanHFSociety Disclosures Consulting/Advisory Board: Amgen, Astra
More informationRationale and Practical Aspects of Sacubitril- Valsartan and Ivabradine Use in Heart Failure Patients
Rationale and Practical Aspects of Sacubitril- Valsartan and Ivabradine Use in Heart Failure Patients Javed Butler, MD, MPH, MBA Patrick H. Lehan Professor of Medicine Professor of Physiology Chairman,
More information2016 Update to Heart Failure Clinical Practice Guidelines
2016 Update to Heart Failure Clinical Practice Guidelines Mitchell T. Saltzberg, MD, FACC, FAHA, FHFSA Medical Director of Advanced Heart Failure Froedtert & Medical College of Wisconsin Stages, Phenotypes
More information2/3/2017. Objectives. Effective Heart Failure Management through Evidence Based Practice and Innovation
Effective Heart Failure Management through Evidence Based Practice and Innovation Jennifer Bauerly RN, CHFN, APRN-BC CentraCare Heart and Vascular Center Objectives Describe the scope and impact of heart
More informationEvaluation and Management of Acute Decompensated Heart Failure (HF) with Reduced Ejection Fraction Systolic Heart Failure (HFrEF)(EF<40%
Evaluation and Management of Acute Decompensated Heart Failure (HF) with Reduced Ejection Fraction Systolic Heart Failure (HFrEF)(EF
More informationNew Winners in the World of Heart Failure. Laura Steffens PharmD Candidate 2016 CICU Presentation August 12, 2015
New Winners in the World of Heart Failure Laura Steffens PharmD Candidate 2016 CICU Presentation August 12, 2015 Jessup 2014 Shaking Things Up 2003: FDA approved eplerenone for the treatment of heart failure
More informationLCZ696 A First-in-Class Angiotensin Receptor Neprilysin Inhibitor
The Angiotensin Receptor Neprilysin Inhibitor LCZ696 in Heart Failure with Preserved Ejection Fraction The Prospective comparison of ARNI with ARB on Management Of heart failure with preserved ejection
More informationState-of-the-Art Management of Chronic Systolic Heart Failure
State-of-the-Art Management of Chronic Systolic Heart Failure Michael McCulloch, MD 17 th Annual Cardiovascular Update Intermountain Medical Center December 16, 2017 Disclosures: I have no financial disclosures
More informationManagement Strategies for Advanced Heart Failure
Management Strategies for Advanced Heart Failure Mary Norine Walsh, MD, FACC Medical Director, HF and Cardiac Transplantation St Vincent Heart Indianapolis, IN USA President American College of Cardiology
More informationTherapeutic Targets and Interventions
Therapeutic Targets and Interventions Ali Valika, MD, FACC Advanced Heart Failure and Pulmonary Hypertension Advocate Medical Group Midwest Heart Foundation Disclosures: 1. Novartis: Speaker Honorarium
More informationIntroduction to Heart Failure. Mauricio Velez, M.D. Transplant Cardiologist APACVS 2018 April 5-7 Miami, FL
Introduction to Heart Failure Mauricio Velez, M.D. Transplant Cardiologist APACVS 2018 April 5-7 Miami, FL Disclosures No relevant financial relationships to disclose Objectives and Outline Define heart
More informationSacubitril/valsartan: A New Management Strategy for the Treatment of Heart Failure. Elizabeth Pogge, PharmD, MPH, BCPS, FASCP
Sacubitril/valsartan: A New Management Strategy for the Treatment of Heart Failure Elizabeth Pogge, PharmD, MPH, BCPS, FASCP Disclosure Elizabeth Pogge reports no actual or potential conflicts of interest
More informationLong-Term Care Updates
Long-Term Care Updates July 2015 By Amy Friedman Wilson, PharmD Heart failure (HF) is a clinical condition in which ventricular filling or ejection of blood is structurally or functionally impaired. 1
More informationINIBITORI NEPRILISINA
INIBITORI NEPRILISINA Marco Canepa, MD, PhD Università degli Studi di Genova Cardiologia, Ospedale Policlinico San Martino IRCCS marco.canepa@unige.it ARNI: ANGIOTENSIN RECEPTOR NEPRILYSIN INHIBITORS
More informationCongestive Heart Failure: Outpatient Management
The Chattanooga Heart Institute Cardiovascular Symposium Congestive Heart Failure: Outpatient Management E. Philip Lehman MD, MPP Disclosure No financial disclosures. Objectives Evidence-based therapy
More informationUpdates in Congestive Heart Failure
Updates in Congestive Heart Failure GREGORY YOST, DO JOHNSTOWN CARDIOVASCULAR ASSOCIATES 1/28/2018 Disclosures Edwards speaker on Sapien3 valves (TAVR) Stages A-D and NYHA Classes I-IV Stage A: High risk
More informationHeart Failure: Combination Treatment Strategies
Heart Failure: Combination Treatment Strategies M. McDonald MD, FRCP State of the Heart Symposium May 28, 2011 None Disclosures Case 69 F, prior MIs (LV ejection fraction 25%), HTN No demonstrable ischemia
More informationPharmacological Treatment for Chronic Heart Failure. Dr Elaine Chau HK Sanatorium & Hospital, Hong Kong 3 August 2014
Pharmacological Treatment for Chronic Heart Failure Dr Elaine Chau HK Sanatorium & Hospital, Hong Kong 3 August 2014 1 ACC/AHA 2005 guideline update for Diagnosis & management of CHF in the Adult -SA Hunt
More informationheart failure John McMurray University of Glasgow.
A to Z of RAAS blockade in heart failure John McMurray BHF Cardiovascular Research Centre University of Glasgow. RAAS inhibition in CHF ACE inhibition in patients with low LVEF CHF CONSENSUS Enalapril
More informationModule 1: Evidence-based Education for Health Care Professionals
Module 1: Evidence-based Education for Health Care Professionals Heart Failure is a HUGE Problem Prevalence Incidence Mortality Hospital Discharges Cost 1 5,300,000 660,000 284,965 1,084,000 $34.8 billion
More informationCKD Satellite Symposium
CKD Satellite Symposium Recommended Therapy by Heart Failure Stage AHA/ACC Task Force on Practice Guideline 2001 Natural History of Heart Failure Patients surviving % Mechanism of death Sudden death 40%
More informationFaiez Zannad. Institut Lorrain du Coeur et des Vaisseaux. CIC - Inserm
Faiez Zannad Institut Lorrain du Coeur et des Vaisseaux CIC - Inserm Disclosure Faiez Zannad Grants BG Medicine, Roche Diagnostics. Consultant/Steering committees/event committees/ Data safety Monitoring
More informationDisclosure Statement. Heart Failure: Refreshers and Updates. Objectives. CHF: Chronic Heart Failure. Definitions. Definitions 2/19/2018
Disclosure Statement Heart Failure: Refreshers and Updates Tracy K. Pettinger, PharmD Clinical Associate Professor College of Pharmacy The planners and presenter of this presentation have disclosed no
More informationHeart Failure with Preserved EF (HFPEF) Epidemiology and management
Heart Failure with Preserved EF (HFPEF) Epidemiology and management Karl Swedberg Senior Professor of Medicine Sahlgrenska Academy University of Gothenburg Gothenburg, Sweden e-mail: karl.swedberg@gu.se
More informationCardiovascular Guideline-Driven Pharmacotherapies: Optimizing Management
Cardiovascular Guideline-Driven Pharmacotherapies: Optimizing Management David Parra, Pharm.D., FCCP, BCPS Clinical Pharmacy Program Manager in Cardiology/Anticoagulation VISN 8 Pharmacy Benefits Management
More informationBiomarkers in the Age of Sacubitril/Valsa rten: Has the PARADIGM Changed
Biomarkers in the Age of Sacubitril/Valsa rten: Has the PARADIGM Changed Alan S. Maisel MD FACC Professor of Medicine, University of California, San Diego, Director, CCU and Heart Failure Program San Diego
More informationHeart Failure Therapies State of the Art 2017
Heart Failure Therapies State of the Art 2017 Andrew J. Sauer, MD Assistant Professor Director, Center for Heart Failure Medical Director, Heart Transplantation UNOS Primary Transplant Physician asauer@kumc.edu
More informationTreatment Of Preserved Cardiac Function Heart Failure with an Aldosterone antagonist (TOPCAT) AHA Nov 18, 2014 Update on Randomized Trials
Treatment Of Preserved Cardiac Function Heart Failure with an Aldosterone antagonist (TOPCAT) AHA Nov 18, 2014 Update on Randomized Trials Marc A. Pfeffer, MD, PhD; Brian Claggett, PhD; Susan F. Assmann,
More informationClinical Pearls Heart Failure Cardiology/New Drugs
Clinical Pearls Heart Failure Cardiology/New Drugs Friday, September 9 th, 2016 Heidi Burres, PharmD, BCACP MTM Pharmacist Fairview Pharmacy Services Thank You to XYZ Event Sponsor(s): Wi-fi Information:
More informationHeart Failure Management Update
Heart Failure Management Update Rafique Ahmed, MD, PhD, FACC, FCPS Consultant Cardiac Electrophysiologist Baltimore, Maryland, USA Heart Failure - Definition The situation when the heart is incapable of
More information